Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23875206 | 1.00 | HSD11B1 (0.50) | HSD11B1GRM1GRIN2BPLD1DRD4 | |
| SCHEMBL23875353 | 0.83 | PLD1 (0.52) | HSD11B1GRM1GRIN2BPLD1KDM4E | |
| SCHEMBL19416591 | 0.81 | GRM1 (0.55) | GRM1PLD1DRD4KDM4EALDH1A1 | |
| SCHEMBL23875155 | 0.81 | KDM4E (0.48) | HSD11B1GRM1GRIN2BPLD1DRD4 | |
| SCHEMBL15858045 | 0.81 | GRM1 (0.55) | GRM1PLD1DRD4KDM4EALDH1A1 | |
| SCHEMBL13380529 | 0.81 | GRM1 (0.55) | GRM1PLD1DRD4KDM4EALDH1A1 | |
| SCHEMBL28768958 | 0.80 | HSD11B1 (0.49) | HSD11B1GRM1GRIN2BPLD1DRD4 | |
| SCHEMBL28768957 | 0.80 | HSD11B1 (0.62) | HSD11B1GRM1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL29991351 | 0.80 | GRIN2B (0.49) | HSD11B1GRM1GRIN2BPLD1KDM4E | |
| SCHEMBL26972296 | 0.79 | GRM1 (0.47) | HSD11B1GRM1GRIN2BPLD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| WO-2021194878-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | HSD11B1 2021/4885GRM1 2650/4885GRIN2B 2011/4885 |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | HSD11B1 2692/4885GRM1 2546/4885GRIN2B 2082/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | HSD11B1 4671/4885GRM1 711/4885GRIN2B 596/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | HSD11B1 2021/4885GRM1 2650/4885GRIN2B 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.